Article

Daily Medication Pearl: Voriconazole (Vfend)

Voriconazole (Vfend) is an azole antifungal indicated for the treatment of invasive aspergillosis and Candidemia in non-neutropenics and other deep tissue Candida infections.

Medication Pearl of the Day: Voriconazole (Vfend)

Indication: Voriconazole (Vfend) is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with invasive aspergillosis and Candidemia in non-neutropenics and other deep tissue Candida infections.

Insight:

  • Dosing: May start from 4 mg/kg/day and extend to 9 mg/kg/day based on the patient.
  • Dosage forms: Tablets 50 mg, 200 mg.
  • Adverse events: The most common adverse reactions (incidence ≥2%) were visual disturbances, fever, nausea, rash, vomiting, chills, headache, liver function test abnormal, tachycardia, and hallucinations.
  • Mechanism of action: Voriconazole is an antifungal drug.

Source:

https://labeling.pfizer.com/showlabeling.aspx?id=618

Related Videos
Senior Doctor is examining An Asian patient.
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC